Characterization of human influenza viruses in lebanon during 2010-2011 and 2011-2012 post-pandemic seasons

Intervirology

Volumn 57, Issue 6, 2014, Pages 344-352

  Zaraket, Hassan ^a,b   Dapat, Clyde ^c   Ghanem, Soha ^a   Ali, Zainab ^a   Lteif, Mireille ^a   Kondo, Hiroki ^c   Dapat, Isolde C ^c   Saito, Kousuke ^c   Kayali, Ghazi ^b   Suzuki, Hiroshi ^c,d   Dbaibo, Ghassan ^a   Saito, Reiko ^c  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^d NIIGATA SEIRYO UNIVERSITY   (Japan)

Author keywords

Antiviral drug susceptibility; Influenza virus; Lebanon; Middle East; Neuraminidase inhibitors; Pandemic H1N1

Indexed keywords

AMANTADINE; LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; ZANAMIVIR; ANTIVIRUS AGENT; CYCLOPENTANE DERIVATIVE; GUANIDINE DERIVATIVE; SIALIDASE;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; FLU LIKE SYNDROME; GENE MUTATION; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; HUMAN; IC50; INFLUENZA A; INFLUENZA B; INFLUENZA VIRUS; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; LEBANON; MAJOR CLINICAL STUDY; MOLECULAR PHYLOGENY; NASOPHARYNX; NOSE SMEAR; NUCLEOTIDE SEQUENCE; PANDEMIC INFLUENZA; PHENOTYPIC VARIATION; PREVALENCE; SEASONAL INFLUENZA; SEASONAL VARIATION; VIRUS ISOLATION; VIRUS RESISTANCE; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; DRUG EFFECTS; GENETICS; INFLUENZA VIRUS B; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MUTATION; PANDEMIC; PHYLOGENY; VIROLOGY;

CERCOPITHECINE HERPESVIRUS 1; HUMAN INFLUENZA VIRUS; INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE;

AMANTADINE; ANTIVIRAL AGENTS; CYCLOPENTANES; DRUG RESISTANCE, VIRAL; GUANIDINES; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA, HUMAN; LEBANON; MICROBIAL SENSITIVITY TESTS; MUTATION; NEURAMINIDASE; OSELTAMIVIR; PANDEMICS; PHYLOGENY; ZANAMIVIR;

EID: 84918804659     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000365758     Document Type: Article

References (29)

1. Nicholson KG, Wood JM, Zambon M: Influenza. Lancet 2003; 362: 1733-1745.
2. Treanor J: Influenza vaccine -outmaneuvering antigenic shift and drift. N Engl J Med 2004; 350: 218-220.
3. Novel Swine-Origin Influenza AVIT; Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, Gubareva LV, Xu X, Bridges CB, Uyeki TM: Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360: 2605-2615.
4. WHO: WHO (2010 March) weekly epidemiology report. http://www.Who.Int/wer. 2010.
5. WHO: WHO (June 2012) weekly epidemiology report. http://www.Who.Int/wer. 2012.
6. Hurt AC, Ernest J, Deng YM, Iannello P, Besselaar TG, Birch C, Buchy P, Chittaganpitch M, Chiu SC, Dwyer D, Guigon A, Harrower B, Kei IP, Kok T, Lin C, McPhie K, Mohd A, Olveda R, Panayotou T, Rawlinson W, Scott L, Smith D, D'Souza H, Komadina N, Shaw R, Kelso A, Barr IG: Emergence and spread of oseltamivir-resistant a (H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 2009; 83: 90-93.
7. Meijer A, Lackenby A, Hungnes O, Lina B, van-der-Werf S, Schweiger B, Opp M, Paget J, van-de-Kassteele J, Hay A, Zambon M; European Influenza Surveillance Scheme: Oseltamivir-resistant influenza virus a (H1N1), Europe, 2007-08 Season. Emerg Infect Dis 2009; 15: 552-560.
8. Hayden FG: Antiviral resistance in influenza viruses -implications for management and pandemic response. N Engl J Med 2006; 354: 785-788.
9. Ison MG: Antivirals and resistance: Influenza virus. Curr Opin Virol 2011; 1: 563-573.
10. Hurt AC, Chotpitayasunondh T, Cox NJ, Daniels R, Fry AM, Gubareva LV, Hayden FG, Hui DS, Hungnes O, Lackenby A, Lim W, Meijer A, Penn C, Tashiro M, Uyeki TM, Zambon M; WHO Consultation on Pandemic Influenza A (H1N1) 2009 Virus Resistance to Antivirals: Antiviral resistance during the 2009 influenza A H1N1 pandemic: Public health, laboratory, and clinical perspectives. Lancet Infect Dis 2012; 12: 240-248.
11. Zaraket H, Kondo H, Tabet C, Hanna-Wakim R, Suzuki Y, Dbaibo GS, Saito R, Suzuki H: Genetic diversity and antiviral drug resistance of pandemic H1N1 2009 in Lebanon. J Clin Virol 2011; 51: 170-174.
12. Suzuki Y, Saito R, Sato I, Zaraket H, Nishikawa M, Tamura T, Dapat C, Caperig-Dapat I, Baranovich T, Suzuki T, Suzuki H: Identification of oseltamivir resistance among pandemic and seasonal influenza A (H1N1) viruses by an His275Tyr genotyping assay using the cycling probe method. J Clin Microbiol 2011; 49: 125-130.
13. Suzuki Y, Saito R, Zaraket H, Dapat C, Caperig-Dapat I, Suzuki H: Rapid and specific detection of amantadine-resistant influenza A viruses with a Ser31Asn mutation by the cycling probe method. J Clin Microbiol 2010; 48: 57-63.
14. Dapat IC, Dapat C, Baranovich T, Suzuki Y, Kondo H, Shobugawa Y, Saito R, Suzuki H, Japanese Influenza Collaborative Study Group: Genetic characterization of human influenza viruses in the pandemic (2009-2010) and post-pandemic (2010-2011) periods in Japan. PLoS One 2012; 7: E36455.
15. Dapat C, Saito R, Kyaw Y, Naito M, Hasegawa G, Suzuki Y, Dapat IC, Zaraket H, Cho TM, Li D, Oguma T, Baranovich T, Suzuki H: Epidemiology of human influenza A and B viruses in Myanmar from 2005 to 2007. Intervirology 2009; 52: 310-320.
16. Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR: Universal primer set for the fulllength amplification of all influenza A viruses. Arch Virol 2001; 146: 2275-2289.
17. NIMR: February 2012 interim report. http://www.Nimr.Mrc.Ac.Uk/who-influenza-centre/annual-And-interim-reports/. 2012.
18. Hurt AC, Barr IG, Hartel G, Hampson AW: Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Res 2004; 62: 37-45.
19. Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE Jr, Wilson IA: Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 2010; 328: 357-360.
20. Hurt AC, Lee RT, Leang SK, Cui L, Deng YM, Phuah SP, Caldwell N, Freeman K, Komadina N, Smith D, Speers D, Kelso A, Lin RT, Maurer-Stroh S, Barr IG: Increased detection in Australia and Singapore of a novel influenza A(H1N1) 2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro Surveill 2011; 16.
21. WHO: WHO (2010 August) pandemic H1N1 2009. Update 112. http://www.Who.Int/csr/disease/swineflu/. 2010.
22. Pica N, Hai R, Krammer F, Wang TT, Maamary J, Eggink D, Tan GS, Krause JC, Moran T, Stein CR, Banach D, Wrammert J, Belshe RB, Garcia-Sastre A, Palese P: Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci USA 2012; 109: 2573-2578.
23. Palese P, Wang TT: Why do influenza virus subtypes die out? A hypothesis. MBio 2011; 2: E00150-e00111.
24. Storms AD, Gubareva LV, Su S, Wheeling JT, Okomo-Adhiambo M, Pan CY, Reisdorf E, St George K, Myers R, Wotton JT, Robinson S, Leader B, Thompson M, Shannon M, Klimov A, Fry AM; US Antiviral Resistance Surveillance Working Group: Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, united states, 2010-11. Emerg Infect Dis 2012; 18: 308-311.
25. Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Gehrig N, Kelso A: Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N Engl J Med 2011; 365: 2541-2542.
26. Leang SK, Deng YM, Shaw R, Caldwell N, Iannello P, Komadina N, Buchy P, Chittaganpitch M, Dwyer DE, Fagan P, Gourinat AC, Hammill F, Horwood PF, Huang QS, Ip PK, Jennings L, Kesson A, Kok T, Kool JL, Levy A, Lin C, Lindsay K, Osman O, Papadakis G, Rahnamal F, Rawlinson W, Redden C, Ridgway J, Sam IC, Svobodova S, Tandoc A, Wickramasinghe G, Williamson J, Wilson N, Yusof MA, Kelso A, Barr IG, Hurt AC: Influenza antiviral resistance in the Asia-Pacific region during 2011. Antiviral Res 2013; 97: 206-210.
27. Iioka F, Sada R, Maesako Y, Nakamura F, Ohno H: Outbreak of pandemic 2009 influenza A/H1N1 infection in the hematology ward: Fatal clinical outcome of hematopoietic stem cell transplant recipients and emergence of the H275Y neuraminidase mutation. Int J Hematol 2012; 96: 364-369.
28. Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Leang SK, Lee RT, Iannello P, Gehrig N, Shaw R, Wark P, Caldwell N, Givney RC, Xue L, Maurer-Stroh S, Dwyer DE, Wang B, Smith DW, Levy A, Booy R, Dixit R, Merritt T, Kelso A, Dalton C, Durrheim D, Barr IG: Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis 2012; 206: 148-157.
29. Boltz DA, Douangngeun B, Phommachanh P, Sinthasak S, Mondry R, Obert C, Seiler P, Keating R, Suzuki Y, Hiramatsu H, Govorkova EA, Webster RG: Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic. J Gen Virol 2010; 91: 949-959.